Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 6, 2006, Pages 959-962

  Henderson, Brooke C ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Angiotensin II; ECM remodeling; Endothelial myocyte coupling; Heart failure; MMP; TIMP

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

CELL ACTIVATION; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; EDITORIAL; HEART DILATATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HOMEOSTASIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANIMALS; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; MODELS, CARDIOVASCULAR; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; RATS; RECEPTORS, ANGIOTENSIN;

CANIS FAMILIARIS;

EID: 33751229302     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.09.001     Document Type: Editorial

References (70)

1. Takenaka H., Kihara Y., Iwanaga Y., Onozawa Y., Toyokuni S., and Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol. 41 (2006) 989-997
2. Funabiki K., et al. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and LV stiffness in dogs with heart failure. Am. J. Physiol. 287 6 (2004) H2487-H2492
3. Scarabelli T., Stephanou A., Rayment N., et al. Apoptosis of endothelial cells precedes myocytes cell apoptosis in ischemic/reperfusion injury. Circulation 104 (2001) 253-256
4. Fukuchi M., Watanabe J., and Kumagai K. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol. 37 (2001) 1436-1442
5. Roberts J.T., and Wearn J.T. Quantitative changes in the capillary-muscle relationship in human hearts during normal growth and hypertrophy. Am. J. Heart (1941) 617-633
6. Michel J.-B., Salzmann J.-L., Nlom M.O., Bruneval P., Barres D., and Camilleri J.P. Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy. Basic Res. Cardiol. 81 (1986) 142-154
7. Capasso J.M., Robinson T.F., and Aneversa P. Alterations in collagen cross-linking impair myocardial contractility in the mouse heart. Circ. Res. 65 (1989) 1657-1664
8. Matsubara L.S., Matsubara B.B., Okashi M.P., Cicogna A.C., and Janicki J.S. Alterations in myocardial collagen content affect rat papillary muscle function. Am. J. Physiol. 279 (2000) H1534-H1539
9. Miller A., Mujumdar V., Palmer L., Bower J.D., and Tyagi S.C. Reversal of EE dysfunction by folic acid in homocysteinemic hypertensive rats. Am. J. Hypertens. 15 (2002) 157-163
10. Cox M.J., Sood H.S., Hunt M.J., Chandler D., Henegar J.R., Aru G.M., et al. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am. J. Physiol. 282 (2002) H1197-H1205
11. Shizukuda Y., and Buttrick P.M. Oxygen free radicals and heart failure: new insight into an old question. Am. J. Physiol. 283 2 (2002) L237-L238
12. Hunt M.J., Aru G.M., Hayden M.R., Moore C.K., Hoit B.D., and Tyagi S.C. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am. J. Physiol. 283 2 (2002) L239-L245
13. Amann K., Breitbach M., Ritz E., and Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J. Am. Soc. Nephrol. 9 (1998) 1018-1022
14. Miller A., Mujumdar V., Shek E., Guillot J., Angelo M., Pakmer L., and Tyagi S.C. Hyperhomocysteinemia induces multiorgan damage. Heart Vessels 15 3 (2000) 135-143
15. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., and Lutucuta S. Simavastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
16. Aimes R.T., and Quigley J.P. MMP-2 is an interstitial collagenase. J. Biol. Chem. 270 (1995) 5872-5876
17. Senior R.M., Griffin G.L., Eliszar C.J., Shapiro S.D., Goldberg G.I., and Welgus H.G. Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 266 (1991) 7870-7875
18. Rucklidge G.J., Milne G., McGaw B.A., Milne E., and Robins S.P. Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim. Biophys. Acta 11 (1992) 1156-1157
19. Hoppeler H., and Kayar S.R. Capillary and oxidative capacity of muscles. News Physiol. Sci. 3 (1988) 113-116
20. Henderson A.H., Lewis M.J., Shah A.M., and Smith J.A. Endothelium, endocardium, and cardiac contraction. Cardiovasc. Res. 26 4 (1992) 305-308
21. Smith J.A., Shah A.M., Fort S., and Lewis M.J. The influence of endocardial endothelium on myocardial contraction. Trends Pharmacol. Sci. 13 (1992) 113-116
22. Mebazaa A., Wetzel R., Cherian M., and Abraham M. Comparison between endothelial and great vessel endothelial cells: morphology, growth, and prostaglandin release. Am. J. Physiol. 268 (1995) H250-H259
23. Pinsky D.J., Patton S., Mesaros S., Brovkovych V., Kubaszewski E., Grunfeld S., et al. Mechanical transduction of NO synthesis in the beating heart. Circ. Res. 81 (1997) 372-379
24. Gattuso A., Mazza R., Pellegrino D., and Tota B. Endocardial endothelium (EE) mediates luminal acetylcholine-nitric oxide signaling in isolated frog heart. Am. J. Physiol. 276 (1999) H633-H641
25. Wang J., and Morgan J.P. EE modulates myofilament Ca2+ responsiveness in aequorin-loaded ferret myocardium. Circ. Res. 70 (1992) 754-760
26. Belch J.J.F., Chopra M., Hutchinson S., Lorimer R., Sturrock R.D., Forbes C.D., et al. Free radical pathology in chronic arterial disease. Free Radical Biol. Med. 6 (1989) 375-378
27. Prasad K., Gupta J.B., Kalra J., Lee P., Mantha S.V., and Bharadwaj B. Oxidative stress as a mechanism of CHF in chronic volume overload in canine model. J. Mol. Cell. Cardiol. 28 (1996) 375-385
28. Cesselli D., Jakoniuk I., Barlucchi L., Beltrami A.P., Hintze T.H., Nadal-Ginard B., et al. Oxidative stress-mediated cardiac cell death is major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res. 89 (2001) 279-286
29. Pimentel D.R., Amin J.K., Xiao L., Miller T., Viereck J., Oliver-Krasinski J., et al. ROS mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 89 (2001) 453-460
30. Diaz-Velez C.R., Garcia-Castineiras S., Mendoza-Ramos E., and Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am. J. Heart 131 (1996) 146-152
31. Draper H.H., Dhanakoti S.N., Hadley M., and Piche P.A. Malondialdehyde in biological systems. In: Chow C.K. (Ed). Cellular antioxidant defense mechanisms vol. II (1988), CRC press, Boca Raton, Fla 97-109
32. Ambrosio G., and Flaherty J.J. Membrane lipid peroxidation induced by oxygen radical generation at reflow in reperfused heart. J. Clin. Invest. 87 (1991) 2056-2066
33. Babior B.M. NADPH oxidase: an update. Blood 93 (1999) 1464-1476
34. Wilcox C.S., and Welch W.J. Oxidative stress: cause or consequence of hypertension. Exp. Biol. Med. (Maywood) 226 (2001) 619-620
35. McCord J.M., and Fridovich I. Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244 (1969) 6049-6055
36. Roos D., Wening R.S., and Wyss S.R. Protection of human neutrophils by endogenous catalase: studies with cells from catalase-deficient individuals. J. Clin. Invest. 65 (1980) 1515-1522
37. Lawrence R.A., and Burk R.F. Species, tissue and subcellular distribution of selenium dependent, glutathione peroxidase activity. J. Nutr. 108 (1978) 211-215
38. Carr A., and Frei B. The role of natural antioxidants in preserving the biological activity of endothelial-derived nitric oxide. Free Radical Biol. Med. 15 28(12) (2000) 1806-1814
39. Tyagi S.C., Ratajska A., and Weber K.T. Myocardial matrix metalloproteinases: localization and activation. Mol. Cell. Biochem. 126 (1993) 49-59
40. Tyagi S.C. Proteinases and myocardial extracellular matrix turnover. Mol. Cell. Biochem. 168 (1997) 1-12
41. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular MMP in vitro. I. Clin. Invest. 98 (1996) 2572-2579
42. Laycock S.K., McMurray J., Kane K.A., and Parratt J.R. Effects of chronic norepinephrine administration on cardiac function in rats. J. Cardiovasc. Pharmacol. 26 (1995) 584-589
43. Givertz M.M., and Colucci W.S. New targets for heart-failure therapy: endothelin, inflammatory cytokines, a oxidative stress. Lancet 352 (1998) SI34-SI38
44. Chen C.Y., Huang Y.L., and Lin T.H. Association between oxidative stress and cytokine production in nickel-treated rats. Arch. Biochem. Biophys. 15 356(2) (1998) 127-132
45. Tyagi S.C., Hayden M.R., and Hall J.E. Role of angiotensin in angiogenesis and cardiac fibrosis in heart failure. In: Dhalla N.S., Zahradka P., Dixon I.M.C., and Beamish R.E. (Eds). Angiotensin II receptor blockade: physiological and clinical implications. Progress in experiential cardiology vol. 2 (1998), Kluwer Academic Publishers, Boston 537-549
46. Varin R., Mulder P., Tamion F., Richard V., Henry J.P., Lallemand F., et al. Improvement of endothelial function by chronic ACEI in heart failure: role of NO, prostanoids, oxidant stress and bradykinin. Circulation 102 (2000) 351-356
47. Li P., Chappell M.C., Ferrario C.M., and Brosnihan K.B. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing NO. Hypertension 29 1 (1997) 394-400
48. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Muge A., et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH/NADPH-oxidases. Cardiovasc. Res. 44 (1999) 215-222
49. Tyagi S.C. Proteinases and myocardial ECM turnover. Mol. Cell. Biochem. 168 (1997) 1-12
50. Nagase H., and Woessner J.F. Matrix metalloproteinase. J. Biol. Chem. 274 (1999) 21491-21494
51. Larsson H., Sjoblom T., Dixelius J., Ostman A., et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 60 (2000) 6723-6729
52. Mansell A., Reincke A., et al. The serine protease inhibitor antithrombin II inhibits LPS-mediated NFkB activation by TLR-4. FEBS Lett. 508 (2001) 313-317
53. Moses M.A., and Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J. Cell. Biochem. 47 (1991) 230-235
54. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., and Iwata K. Growth-promoting activity of TIMP-1 for a wide range of cells. FEBS Lett. 298 (1992) 29-32
55. Tyagi S.C., Meyer L., Kumar S.G., Schmaltz R.A., Reddy H.K., and Voelker D.J. Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Can. J. Cardiol. 12 (1996) 353-362
56. Lindsay M.M., Maxwell P., and Dunn F.G. TIMP-1: a marker of LV diastolic dysfunction and fibrosis in hypertension. Hypertension 40 (2002) 136-141
57. Frears E.R., Zhang Z., Blake D.R., O'Connell J.P., and Winyard P.G. Inactivation of TIMP-1 by peroxynitrite. FEBS Lett. 381 (1996) 21-24
58. Nemeth J.A., and Goolsby C.L. TIMP-2, a growth-stimulatory protein from SV40 transformed human fibroblasts. Exp. Cell Res. 207 (1993) 376-382
59. Baker A.H., Zaltsman A.B., George S.J., and Newby A.C. Divergent effects of TIMP-1,-2,-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. 101 (1998) 1478-1487
60. Tummalapalli C.M., Heath B.J., and Tyagi S.C. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J. Cell. Biochem. 80 4 (2001) 512-521
61. Radomski A., Sawicki G., Olson D.M., and Radomski M.W. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br. J. Pharmacol. 125 (1998) 1455-1462
62. Tyagi S.C., Kumar S.G., and Borders S. Reduction-oxidation (Redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J. Cell. Biochem. 61 (1996) 139-151
63. Siwik D.A., Pagano P.J., and Colucci W.S. Oxidative stress regulates collagen synthesis and MMP activity in cardiac fibroblasts. Am. J. Physiol. 280 (2001) C53-C60
64. Stricklin G.P., and Hoidal J.R. Oxidant-mediated inactivation of TIMP. Matrix Suppl. 1 (1992) 325
65. Shabani F., McNeil J., and Tippett L. The oxidative inactivation of TIMP-1 by HOCl is suppressed by ant-rheumatic drugs. Free Radical Res. 28 2 (1998) 115-123
66. Rohde L.E., et al. MMP inhibitors attenuates early LV enlargement in experimental MI in mice. Circulation 99 (1999) 3063-3070
67. Spinale F.G., et al. MMP inhibition during congestive heart failure. Circ. Res. 85 (1999) 364-376
68. Linz W., Wiemer G., and Scholkens B.A. Contribution of bradykinin to the cardiovascular effects of ramipril. J. Cardiovasc. Pharmacol. 22 Suppl. 9 (1993) S1-S8
69. Johar S., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 20 9 (2006) 1546-1548
70. Linz W., Wiemer G., and Scholkens B.A. Bradykinin prevents left ventricular hypertrophy in rats. J. Hypertens., Suppl. 11 5 (1993) S96-S97